tuneTypical Dose
label-dependent
Amino Acid
Citrulline
tuneTypical Dose
label-dependent
watchEffect Window
Start with 2-12 weeks for most practical outcomes.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Citrulline is a nitric oxide pathway ingredient used to increase blood flow signaling. It is taken for exercise pump, endurance, and vascular support.
Studies in exercise and vascular health show it can raise nitric oxide metabolites and improve blood flow measures. Some trials report improved high intensity exercise performance or reduced blood pressure, while others show no effect. Minority work examines erectile function and migraine, with mixed results. Gastrointestinal upset and headaches can occur at higher doses.
Can increase nitric-oxide substrate availability through conversion pathways. Clinical effects remain mixed by protocol.
Article
Citrulline is usually sold as a nitric oxide supplement. That is directionally right, but incomplete.
The real advantage of oral citrulline is pharmacokinetic. Arginine is the molecule nitric oxide synthase actually uses. But oral arginine is heavily metabolized in the gut and liver before much reaches systemic circulation. Citrulline is absorbed efficiently, bypasses a large part of that first-pass loss, and is converted to arginine mainly in the kidneys. In practice, citrulline often raises plasma arginine more reliably than taking arginine itself.
That is why citrulline can influence blood flow, exercise performance, and possibly erectile function without needing extreme doses.
Citrulline sits inside two overlapping systems.
First is the nitric oxide cycle. Arginine is converted to nitric oxide, and citrulline is left behind. That citrulline can then be recycled back to arginine.
Second is the urea cycle. Citrulline also interacts with ornithine and urea metabolism, which matters for ammonia handling during hard exercise.
Most circulating citrulline is not coming from the nitric oxide pathway. It is produced from glutamine-derived nitrogen in the gut. From there, a large fraction is taken up by the kidneys and turned into arginine via argininosuccinate synthase and argininosuccinate lyase.1
So mechanistically, citrulline is less a direct effector and more a substrate delivery system. It supports downstream arginine, nitric oxide, and urea-cycle dynamics.
Oral citrulline is well absorbed and can drive large increases in plasma citrulline. In human dose-ranging work, citrulline in blood rises close to linearly with dose.
Arginine and ornithine also rise, but not linearly forever. Around moderate oral doses, their increase starts to flatten. The likely explanation is a bottleneck in renal conversion and transport rather than poor intestinal uptake.2
Practical implication: pushing dose higher may keep increasing citrulline levels but gives diminishing returns for the arginine and nitric oxide outcomes most people want.
This is one of citrulline's better-supported domains.
Human trials report improved vascular function markers and lower pressure responses under specific stress conditions. For example, studies in prehypertensive adults and middle-aged men show improvements in arterial stiffness and central hemodynamic measures with citrulline-rich interventions. In young men, citrulline reduced the blood pressure spike during cold-pressor testing.
Important qualifier: effects are context-sensitive. In people who are normotensive at rest, changes are smaller and less reliable. Citrulline looks better at improving impaired vascular responses than lowering already-normal blood pressure.
The best evidence is in high-volume resistance work and repeated-effort settings where fatigue accumulates.
A commonly cited study using `8 g` citrulline malate before weight training found modest early-set effects but larger benefits in later sets, plus reduced delayed soreness over 24 to 48 hours. That pattern makes physiological sense. If citrulline helps delay fatigue via blood flow, metabolite handling, or ammonia buffering, you expect the effect to emerge as fatigue builds, not on the first fresh set.
Not every exercise model improves. One treadmill-to-exhaustion protocol reported a slight decrease in time to exhaustion with acute citrulline dosing. That contradiction likely reflects population and protocol differences, not fraud or impossibility.
Citrulline is not a blanket endurance enhancer. It is more accurate to view it as a conditional aid that can help in specific workloads, especially repeated high-intensity efforts.
Two mechanistic ideas matter most.
One is ammonia handling. During prolonged hard effort, ammonia rises and can interfere with muscle energetics and contractile function. Citrulline can support urea-cycle flux indirectly through ornithine and urea production, which may reduce this fatigue signal.
The second is ATP economy. Some human and animal data suggest citrulline malate can improve energy production efficiency and phosphocreatine recovery kinetics, though this is not perfectly consistent across studies. Signal exists, but certainty is moderate rather than high.
Citrulline has intriguing preclinical data in malnourished or aged models, where it appears to restore suppressed muscle protein synthesis via mTORC1-dependent pathways. That is biologically interesting.
But in healthy humans, whole-body protein synthesis outcomes are mixed. Some studies show improved nitrogen balance, others show no significant effect on leucine oxidation or net protein synthesis.
Bottom line: citrulline may be anti-catabolic in stressed or low-nutrition states, but it is not currently a direct substitute for leucine-rich protein feeding when the goal is maximizing hypertrophy.
The mechanism is straightforward. Better systemic arginine availability can increase nitric oxide signaling and downstream cGMP, which is central to erection physiology.
In mild erectile dysfunction, one small trial found meaningful improvement in erection hardness with `1.5 g/day` citrulline and higher satisfaction than placebo. That is encouraging, but still preliminary. Current evidence supports "possibly helpful," not "replacement for PDE5 inhibitors."
Citrulline does not appear to raise growth hormone at rest, but may amplify exercise-induced GH responses in some settings. IGF-1 and insulin are generally unchanged in resting conditions in the available human work.
There are also reports of increased post-exercise neutrophil oxidative burst with citrulline malate without parallel evidence of oxidative damage. This is biologically interesting but not yet actionable for supplementation decisions.
A small translational package (cell, animal, and small human trial) suggests reduced glutathione may extend nitric oxide signaling by limiting rapid oxidative quenching, increasing nitrite/NO markers versus citrulline alone. This is plausible but still early-stage.
Likely complementary in theory because they support nitric oxide signaling from different angles. Direct, high-quality comparative and combination data are still limited.
Theoretical synergy is plausible via buffering mechanisms, but this is mostly mechanistic extrapolation right now.
Citrulline's tolerability profile is a practical strength.
Acute human doses up to `15 g` were generally well tolerated in the cited work, with less gastrointestinal distress than equivalent high-dose arginine or ornithine boluses. That difference is one reason citrulline became the preferred way to raise arginine exposure.
If your goal is performance or pump support, this is the most defensible approach from current human data:
What to monitor:
If none of those change after 2 to 4 weeks, citrulline is probably not moving the needle enough for you.
Citrulline is best understood as an arginine delivery strategy with good tolerability. Its strongest real-world use cases are improving nitric-oxide-related physiology and helping fatigue resistance in certain training contexts. It is not a guaranteed endurance enhancer and not a magic muscle-builder on its own.
Use it where the mechanism and your goal actually match.
Citrulline gets its name from Citrullus lanatus, the watermelon. Watermelon flesh contains roughly 1.5 to 3.5 mg of citrulline per gram of fresh weight, with the rind containing even higher concentrations. A typical large wedge of watermelon (approximately 280 grams) provides roughly 500 to 800 mg of citrulline.
That sounds meaningful until you compare it to supplemental doses. Most exercise performance studies use 6 to 8 grams of citrulline malate, which provides roughly 3.5 to 5 grams of pure citrulline. You would need to eat roughly 2 to 3 kg of watermelon flesh to reach that range from food alone.3
Watermelon juice concentrates have been studied as a more practical food-based delivery method. Some trials report reduced muscle soreness after exercise with watermelon juice providing around 1.2 grams of citrulline. The effect is smaller and less consistent than with higher supplemental doses, which is exactly what you would expect from the dose-response curve.
So watermelon is a legitimate dietary source of citrulline, and it provides the amino acid in a food matrix with other potentially beneficial compounds (lycopene, potassium). But for clinical or performance-oriented dosing, food sources alone are insufficient. Think of dietary citrulline as a baseline contributor, not a therapeutic dose.
This distinction causes real confusion. Citrulline malate is a combination of L-citrulline and malic acid (malate), typically in a 2:1 ratio by weight. That means a 6-gram dose of citrulline malate delivers approximately 4 grams of citrulline and 2 grams of malate.
The malate component has its own theoretical value. Malate is a tricarboxylic acid (TCA) cycle intermediate, and supplying it could support aerobic energy production under high metabolic demand. This is the rationale for why citrulline malate is sometimes framed as having dual benefits: vascular support from citrulline and metabolic support from malate.
In practice, the evidence that the malate component adds meaningful benefit beyond what citrulline provides alone is thin. Most of the performance studies used citrulline malate as the formulation, so the effects cannot be cleanly separated. A few direct comparisons suggest that L-citrulline alone produces equivalent or very similar plasma arginine elevation, which is the primary outcome of interest for NO-related benefits.4
The practical issue is label accuracy. Independent testing has found that some products marketed as "2:1 citrulline malate" actually contain much less citrulline than claimed, with some products delivering closer to a 1:1 ratio or less. If you are using citrulline malate, verify that the product has third-party testing for both citrulline and malate content. Alternatively, use pure L-citrulline at 3 to 6 grams and eliminate the formulation uncertainty entirely.
Understanding why citrulline raises arginine so effectively requires looking at the full recycling loop.
When endothelial NOS converts arginine to nitric oxide, the byproduct is citrulline. That citrulline is not wasted. It is taken up by the kidneys (and to a lesser extent by vascular endothelial cells themselves) and converted back to arginine through a two-step enzymatic process. First, argininosuccinate synthase combines citrulline with aspartate to form argininosuccinate. Then, argininosuccinate lyase cleaves that intermediate to release arginine and fumarate.5
This recycling pathway means that citrulline can sustain arginine availability through multiple cycles rather than providing a single-pass substrate delivery. Each molecule of citrulline can potentially generate multiple rounds of arginine and nitric oxide production through this loop.
The recycling also operates locally in endothelial cells, which express the necessary enzymes. This local recycling may be more important for vascular NO production than systemic arginine levels, because it maintains arginine availability at the precise site where NOS is active. This is one reason citrulline can support NO signaling even when bulk plasma arginine is not dramatically elevated.
The mechanism connecting citrulline to erectile function is straightforward and well-grounded. Penile erection depends on nitric oxide release from cavernosal nerves and endothelium, which activates guanylate cyclase, increases cyclic GMP, and relaxes smooth muscle in the corpus cavernosum. This is the same pathway targeted by PDE5 inhibitors like sildenafil.
The clinical evidence is limited but directionally positive. In the most cited trial, men with mild erectile dysfunction received 1.5 grams of L-citrulline daily for one month. The erection hardness score improved from 3 (hard enough for penetration but not fully rigid) to 4 (fully rigid) in about half the citrulline group versus less than 9% in the placebo group. No adverse effects were reported.6
That is a meaningful clinical improvement, but the study was small and the population was selected for mild dysfunction. For moderate to severe erectile dysfunction, PDE5 inhibitors remain more reliable. Citrulline may serve as a first-line option for men who prefer a non-pharmaceutical approach to mild symptoms, or as an adjunct to lifestyle interventions (exercise, weight management, cardiovascular risk reduction) that address the underlying endothelial dysfunction.
The dose used in the erectile function trial (1.5 g/day) is lower than typical exercise performance doses (6 to 8 g citrulline malate). Whether higher doses would produce stronger erectile outcomes has not been tested.
Heart failure, particularly heart failure with reduced ejection fraction, is characterized by impaired nitric oxide bioavailability, endothelial dysfunction, and exercise intolerance. These are exactly the domains where citrulline's mechanism is most relevant.
Small human studies in heart failure patients have reported improvements in right ventricular function, pulmonary artery pressure, and exercise tolerance with oral citrulline supplementation. In one study, citrulline improved right ventricular ejection fraction and reduced pulmonary vascular resistance in patients after cardiac surgery.7
These are encouraging signals, but the studies are small and the populations are specific. Citrulline is not a treatment for heart failure. It is a potential adjunct that addresses one component of the pathophysiology (impaired NO signaling) without targeting the primary structural or neurohormonal drivers.
For people with diagnosed heart failure, any supplementation should be discussed with their cardiology team. The interaction with existing vasodilators, diuretics, and neurohormonal therapies needs individual assessment.
The optimal timing for citrulline depends on what you are trying to achieve.
For acute exercise performance, take citrulline 60 to 90 minutes before training. Plasma citrulline peaks within about 30 to 60 minutes of oral ingestion, and the downstream arginine elevation follows shortly after. This timing aligns citrulline's peak availability with the start of your training session.
For chronic vascular support or blood pressure management, consistent daily dosing matters more than precise timing. Split doses (morning and evening) may provide more stable arginine availability throughout the day than a single large dose.
For erectile function support, daily dosing builds a sustained baseline of improved arginine availability. The effect is not acute like a PDE5 inhibitor. It accumulates over days to weeks of consistent use.
Most oral citrulline is handled by the kidneys, where it is converted to arginine in proximal tubules.
↩Human pharmacokinetic work shows plasma citrulline rises linearly, while arginine and ornithine eventually show diminishing dose response.
↩Watermelon flesh contains approximately 1.5-3.5 mg citrulline per gram of fresh weight, requiring roughly 2-3 kg of flesh to match a typical supplemental dose of 6-8 grams citrulline malate.
↩Direct comparisons suggest L-citrulline alone produces similar plasma arginine elevation to citrulline malate, and independent testing has found label accuracy issues in some citrulline malate products.
↩The citrulline-arginine recycling pathway operates through argininosuccinate synthase and argininosuccinate lyase, allowing multiple rounds of arginine regeneration from a single citrulline molecule.
↩In a controlled trial of men with mild erectile dysfunction, 1.5 g/day L-citrulline for one month improved erection hardness scores in approximately half of participants versus less than 9% with placebo.
↩Small studies in heart failure patients report improvements in right ventricular function and pulmonary vascular resistance with oral citrulline supplementation following cardiac surgery.
↩Outcomes
Safety
Evidence
PubMed evidence scan for "Citrulline" + "human trial".
Population: Adults in variable clinical and non-clinical settings
Dose protocol: Label or study-specific formulation and dose
Key findings: Mixed to weak, often context-specific
Notes: Strong heterogeneity in dosing, endpoints, and outcome quality
Mixed to weak, often context-specific
PubMed evidence scan for "Citrulline" + "systematic review".
Population: Adult human cohorts; mixed conditions and comparators
Dose protocol: Variable
Key findings: No consistent pooled superiority across all outcomes
Notes: Inconsistent methods and selective reporting in available literature
No consistent pooled superiority across all outcomes
Bahari H, Ramezani E, Malekahmadi M. Citrulline supplementation in postmenopausal women: a systematic review of vascular, muscular, and metabolic effects. BMC Womens Health. 2026;26(1):116. doi:10.1186/s12905-026-04277-6. PMID:41588439.
Population: Postmenopausal women aged 50 to 75 years across 12 randomized controlled trials.
Dose protocol: Citrulline supplementation across 12 RCTs (360 postmenopausal women, 4-8 weeks)
Key findings: Systolic BP reductions up to 9 mmHg in hypertensive participants. Arterial stiffness and endothelial function mixed. Muscle outcomes improved only with resistance training. No consistent metabolic effects.
Notes: Best population-specific SR for citrulline in postmenopausal women. Supports vascular benefit in hypertensive subgroup.
This systematic review synthesized 12 RCTs (360 postmenopausal women) examining citrulline supplementation for vascular, muscular, and metabolic outcomes. The most consistent finding was systolic blood pressure reduction (up to 9 mmHg) in hypertensive participants. Arterial stiffness and endothelial function results were mixed. Muscle outcomes improved only when citrulline was combined with resistance training. Metabolic parameters showed no consistent effects. No adverse effects were reported. The review highlights that citrulline's vascular benefits appear most relevant in hypertensive postmenopausal women, while broader metabolic claims lack consistent support.